Bell Bank Has $12.09 Million Position in AbbVie Inc. $ABBV

Bell Bank lessened its stake in shares of AbbVie Inc. (NYSE:ABBV) by 12.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 52,915 shares of the company’s stock after selling 7,333 shares during the period. AbbVie accounts for about 0.5% of Bell Bank’s portfolio, making the stock its 25th biggest position. Bell Bank’s holdings in AbbVie were worth $12,091,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Chelsea Counsel Co. acquired a new stake in shares of AbbVie during the 3rd quarter worth $26,000. Texas Capital Bancshares Inc TX acquired a new position in AbbVie in the third quarter valued at about $31,000. Evolution Wealth Management Inc. bought a new stake in AbbVie during the second quarter worth about $26,000. Caitlin John LLC bought a new stake in AbbVie during the third quarter worth about $33,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in AbbVie during the third quarter worth about $41,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a report on Wednesday, January 28th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their price target for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Royal Bank Of Canada began coverage on AbbVie in a research note on Tuesday, February 24th. They set an “outperform” rating and a $260.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Price Performance

Shares of ABBV opened at $209.46 on Friday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company has a market capitalization of $370.37 billion, a price-to-earnings ratio of 88.76, a price-to-earnings-growth ratio of 0.73 and a beta of 0.34. The business has a 50-day moving average of $221.96 and a 200-day moving average of $224.62.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Company outlook and dividend expectations — Analysts and commentators highlight AbbVie’s strong 2026 guidance and the likelihood of future dividend increases, driven by cash flow from Humira/Imbruvica/oncology and growth in the dermatology portfolio; that narrative supports income investors and dividend yield buyers. AbbVie: Strong 2026 Outlook, Expect Dividend Increases
• Positive Sentiment: Clinical and real‑world data boost dermatology franchise — AbbVie announced new clinical and real‑world evidence for risankizumab (psoriasis/psoriatic arthritis) and upadacitinib (atopic dermatitis), plus Phase‑3 data for vitiligo and alopecia areata to be presented at AAD 2026. Strong safety/efficacy reads can support durable revenue and reduce investor uncertainty around launches. AbbVie to Highlight New Clinical and Real-World Evidence…
• Positive Sentiment: Analyst estimate tweak — Erste Group modestly raised its FY2027 EPS estimate for AbbVie, signaling incremental confidence in earnings power (small change but supportive vs. downside fears). MarketBeat AbbVie Profile
• Neutral Sentiment: Allergan Aesthetics (AbbVie unit) scientific presence — Allergan is presenting multiple evidence‑based posters and product positioning (JUVÉDERM, HA injectables) at AMWC, reinforcing aesthetics growth and brand leadership but with limited immediate revenue impact. Allergan Aesthetics Reinforces Scientific Differentiation…
• Neutral Sentiment: Dividend yield framing for investors — Retail‑focused pieces (The Motley Fool) calculate how many ABBV shares generate targeted dividend income; useful for income investors but not an earnings catalyst. Here’s How Many Shares of AbbVie (ABBV) Stock You’d Need…
• Negative Sentiment: Recent price weakness & value debate — Coverage noting recent share‑price declines and questions about valuation may pressure sentiment in the short term; headline focus on near‑term multiple compression can spur selling even as fundamentals are debated. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

Insiders Place Their Bets

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.25% of the company’s stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.